News & Updates

The addition of capivasertib (C) to fulvestrant (F) results in better health-related quality of life (HRQoL), except for diarrhoea, in patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer when compared to placebo plus F, according to the phase III CAPItello-291 study presented at SABCS 2023.

Body mass index (BMI) has some bearing on the efficacy of different adjuvant chemotherapy schedules in patients with early breast cancer, suggest the results of the GIM2 study, which were presented at the recent SABCS 2023. Additionally, dose-dense (DD) chemotherapy appears to be the better treatment strategy regardless of a patient’s BMI.

A prospective study from Singapore provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in individuals with cancer.